Connectome Raises €1.7M To Scale Personalised Brain Health Platform

The round was led by Redstone, with participation from early-stage investors including Concept Ventures and Octopus, as well as strategic investors and angels across Europe and the US. It also includes €103.6k ($120k) in non-dilutive public funding alongside private investment.

Connectome was founded in 2024 by Scherdel and Dr. Rufus Mitchell-Heggs, both experienced neuroscientists with personal insight into brain-related conditions. Scherdel has led global R&D in consumer health, worked with the WHO, and advised health and tech startups, while Dr. Mitchell-Heggs specialises in computational neuroscience and leads the development of neural biomarkers.

Read Also - Pickmybrain Raises €1.8M Pre-seed To Expand AI Digital Brains Platform

The company focuses on improving how brain activity is understood by offering personalised insights into cognitive health. Its approach tracks how brain function changes over time in relation to lifestyle, environment, and overall health, rather than relying on one-time measurements.

Built on research from Imperial College London Connectome’s technology identifies measurable patterns in everyday behaviour and brain activity. This allows for continuous monitoring and a more accurate understanding of cognitive changes in real-world settings.

The platform has potential applications in areas such as ADHD and dementia, enabling earlier detection and better management of cognitive conditions. By combining brain data with lifestyle factors like sleep and activity Connectome provides a more personalised and meaningful view of brain health.

The company said the LUCIID study will continue to examine how repeated measurements can reliably define individual brain baselines and improve methods for interpreting changes in brain activity using contextual data.

The new funding will help launch the product with select partners and support further research to expand into new use cases beyond lifestyle and wearable applications.

Lucas Scherdel, CEO of Connectome, said, “We started Connectome to address a growing gap: while physical health measurement has advanced rapidly, our ability to understand and protect the brain has not kept pace. Cognitive capacity underpins how we think, work, relate, and age, yet it remains poorly understood. Evidence shows cognitive health is quietly deteriorating at scale, with rising burnout, brain fog and attention and memory issues, especially among younger generations. Our environments and technologies now place unprecedented demands on the brain, but we lack everyday ways to detect early change or protect long-term cognitive health.

“Connectome exists to close this gap. By measuring brain function longitudinally,we move beyond isolated snapshots to build personalised models of brain function, with the potential to inform future clinical care and disease progression. Understanding the brain is no longer a niche concern it is essential to human wellbeing and societal resilience.”